Quest Diagnostics Incorporated (DGX) Stock Analysis
Range Bound setup
Healthcare · Diagnostics & Research
Sell if holding. At $189.84, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 5.8%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1).
Quest Diagnostics provides clinical laboratory testing services to physicians, hospitals, patients, and consumers, processing ~244M test requisitions in 2025 and generating $11.0B in net revenue. It serves approximately one-third of U.S. adults annually through ~2,400 patient... Read more
Sell if holding. At $189.84, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 5.8%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1). Chart setup: RSI 42 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 63d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Quest Diagnostics Incorporated
Latest news
- Quest Diagnostics Gains Steam With Partnerships, Lifts Outlook - Sahm — Sahm positive
- Quest Diagnostics Stock Gains 5% After Q1 Earnings Exceed Analyst Expectations - TIKR.com — TIKR.com positive
- Quest Diagnostics (NYSE:DGX) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat — MarketBeat positive
- BofA raises Quest Diagnostics stock price target on strong volumes - Investing.com — Investing.com positive
- DGX Q1 Deep Dive: Organic Growth, Consumer Testing Momentum, and Advanced Diagnostics Drive Outlook - StockStory — StockStory positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-03-12Item 5.02LOWTimothy Wentworth, former CEO of Walgreens Boots Alliance, elected as director effective March 9, 2026. Appointed to Compensation and Leadership Development Committee and Quality and Compliance Committee. Prorated RSU grant of approximately $43,000 issued.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $189.84, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 5.8%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1). Chart setup: RSI 42 mid-range, Bollinger mid-band. Prior stop was $181.20. Score 5.3/10, moderate confidence.
Take-profit target: $200.93 (+5.8% upside). Prior stop was $181.20. Stop-loss: $181.20.
Thin upside margin: 5.8%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1); Negative momentum.
Quest Diagnostics Incorporated trades at a P/E of 20.6 (forward 16.3). TrendMatrix value score: 6.4/10. Verdict: Sell.
24 analysts cover DGX with a consensus score of 3.8/5. Average price target: $223.
What does Quest Diagnostics Incorporated do?Quest Diagnostics provides clinical laboratory testing services to physicians, hospitals, patients, and consumers,...
Quest Diagnostics provides clinical laboratory testing services to physicians, hospitals, patients, and consumers, processing ~244M test requisitions in 2025 and generating $11.0B in net revenue. It serves approximately one-third of U.S. adults annually through ~2,400 patient service centers and interfaces with 612,000+ clinician/hospital accounts. Revenue comes primarily from third-party payers including health plans, Medicare, and Medicaid.